ok so Yacov said.....
we are in the process of developing five in one chemical tests. Glucose is the first.
Yavoc gave a corporate snapshot and talked about the directors and how they bring expert knowledge to the company.
Slide on global footprint.
Mentioned approval in China. Yavoc confirmed to my husband he has applied for CFDA approval in five different Provence’s in China. This was five weeks ago and he has not heard anything.
Yavoc gave an overview of the global footprint
May2017 no revenue to now
Gmv has released info to the market with close to 30,0000 patients in 2019 and double revenue “we believe the trend with continue”.
Increase rev by 90%
Product and solutions
Patch is unique device because of the recorder that monitors 24/48 hours
The patch is a six Chanel patch
Sits on Chest for 14 days
9-11 days average
Can swim, shower and even have sex with the patch the problem is we will find out when it was and how long it was hahaha
The other good thing is we are giving the patch away for free. We are charging the hospital and insurance company.
Patch is reimbursed through Medicare.
Private companies are paying more for patch for the same service. referring to USA.
The product is easy because it doesn’t weigh anything. The patient is unaware of the patch: no switches.
The call centre and algorithms detect abnormalities and provide the physician a report.
Prizma reimbursed 127 dollars for 20 min session once a month.
Patch - provide physician with the report.
Recent achievement
138 m with gem over three years
Growing business, 95 percent year on year
Finalised clinical trials in China waiting for final clearance
Yavoc did not seemed slightly concerned regarding the share price. I am a LTH and will continue to hold.
